[go: up one dir, main page]

SG11201407114YA - Novel dosage and formulation - Google Patents

Novel dosage and formulation

Info

Publication number
SG11201407114YA
SG11201407114YA SG11201407114YA SG11201407114YA SG11201407114YA SG 11201407114Y A SG11201407114Y A SG 11201407114YA SG 11201407114Y A SG11201407114Y A SG 11201407114YA SG 11201407114Y A SG11201407114Y A SG 11201407114YA SG 11201407114Y A SG11201407114Y A SG 11201407114YA
Authority
SG
Singapore
Prior art keywords
international
barcelona
aclidinium
llobregat
laurea
Prior art date
Application number
SG11201407114YA
Inventor
Casado Rosa Lamarca
Miquel Serra Gonzalo De
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46210186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201407114Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of SG11201407114YA publication Critical patent/SG11201407114YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0038—Cutting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
    • A61M15/0051—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a tape, e.g. strips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04C—ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS
    • F04C2270/00—Control; Monitoring or safety arrangements
    • F04C2270/04—Force
    • F04C2270/042—Force radial
    • F04C2270/0421—Controlled or regulated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 November 2013 (28.11.2013) WIPOIPCT (10) International Publication Number WO 2013/175013 A1 (51) International Patent Classification: A61K31/46 (2006.01) A61P11/08 (2006.01) A61M15/00 (2006.01) A61K31/573 (2006.01) A61P11/06 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 12382211.6 61/654,224 61/779,578 PCT/EP2013/060808 24 May 2013 (24.05.2013) English English EP US US 25 May 2012 (25.05.2012) 1 June 2012 (01.06.2012) 13 March 2013 (13.03.2013) (71) Applicant: ALMIRALL, S.A. [ES/ES]; Ronda del Gener­ al Mitre 151, E-08022 Barcelona (ES). (72) Inventors: LAMARCA CASADO, Rosa; C/ Laurea Miro 408-410, Sant Feliu de Llobregat, E-08980 Barcelona (ES). DE MIQUEL SERRA, Gonzalo; C/ Laurea Miro 408-410, Sant Feliu de Llobregat, E-08980 Barcelona (ES). (74) Agent: SRINIVASAN, Ravi Chandran; J A Kemp & Co., 14 South Square, Gray's Inn, London Greater London WC1R 5JJ (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) i-H o i> i-H o CJ (54) Title: NOVEL DOSAGE AND FORMULATION (57) Abstract: A pharmaceutical composition for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutic - ally acceptable salt in admixture with pharmaceutically acceptable a dry powder carrier, providing a delivered dose of aclidinium equivalent to about 322 micrograms aclidinium free base.
SG11201407114YA 2012-05-25 2013-05-24 Novel dosage and formulation SG11201407114YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20120382211 EP2666465A1 (en) 2012-05-25 2012-05-25 Novel dosage and formulation
US201261654224P 2012-06-01 2012-06-01
US201361779578P 2013-03-13 2013-03-13
PCT/EP2013/060808 WO2013175013A1 (en) 2012-05-25 2013-05-24 Novel dosage and formulation

Publications (1)

Publication Number Publication Date
SG11201407114YA true SG11201407114YA (en) 2014-12-30

Family

ID=46210186

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201609244PA SG10201609244PA (en) 2012-05-25 2013-05-24 Novel dosage and formulation
SG11201407114YA SG11201407114YA (en) 2012-05-25 2013-05-24 Novel dosage and formulation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201609244PA SG10201609244PA (en) 2012-05-25 2013-05-24 Novel dosage and formulation

Country Status (23)

Country Link
US (2) US20150118312A1 (en)
EP (2) EP2666465A1 (en)
JP (1) JP2015517560A (en)
KR (1) KR20150010757A (en)
CN (1) CN104349776A (en)
AR (1) AR091161A1 (en)
AU (1) AU2013265167B2 (en)
CA (1) CA2871357A1 (en)
CL (1) CL2014003211A1 (en)
CO (1) CO7200262A2 (en)
CR (1) CR20140536A (en)
DO (1) DOP2014000269A (en)
EA (1) EA201401309A1 (en)
HK (1) HK1203050A1 (en)
IL (1) IL235830A0 (en)
IN (1) IN2014DN08421A (en)
MD (1) MD20140131A2 (en)
MX (1) MX2014014041A (en)
PE (1) PE20142441A1 (en)
PH (1) PH12014502619A1 (en)
SG (2) SG10201609244PA (en)
UY (1) UY34829A (en)
WO (1) WO2013175013A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) † 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
RU2646480C2 (en) * 2012-06-01 2018-03-05 Конинклейке Филипс Н.В. Method and system for selecting frequency of analysis of gas composition of arterial blood for newborn
CN105078932A (en) * 2015-09-06 2015-11-25 北京东方百泰生物科技有限公司 Method for increasing fine particle proportion of medicinal preparation and preparation
CN107823193B (en) * 2017-11-16 2021-02-05 广州迈达康医药科技有限公司 Aclidinium bromide inhalation type powder aerosol and preparation method thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688V0 (en) 1979-02-05 1979-02-05 Chiesi Paolo Parma INHALER FOR PULVERULENT MEDICINAL SUBSTANCES, WITH COMBINED DOSER FUNCTION.
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (en) 1984-10-04 1986-09-12 Orion Yhtymae Oy DOSERINGSANORDNING
DE3927170A1 (en) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg INHALATOR
IT1237118B (en) 1989-10-27 1993-05-18 Miat Spa MULTI-DOSE INHALER FOR POWDER DRUGS.
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (en) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg GAS-FREE INHALATION DEVICE
DE69129188T2 (en) 1990-09-26 1998-07-30 Pharmachemie B.V., Haarlem INHALATOR WITH A RESERVOIR FOR MULTIPLE DOSED INHALATION AGENTS, WITH TRANSPORTATION DEVICE AND WITH A VERBAL CHAMBER
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (en) 1992-11-24 1994-05-26 Bayer Ag Multiple dosage powder inhaler - has acceleration channel and dwell chamber for uniformly high drug dispersion
ES2128550T3 (en) 1992-12-18 1999-05-16 Schering Corp INHALER FOR POWDERED MEDICINES.
DK0837710T3 (en) 1995-06-21 2002-04-02 Sofotec Gmbh & Co Kg Pharmaceutical powder cartridge with integrated dosing device and powder inhaler inhaler
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
DE10129703A1 (en) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Atomizing system for a powder mixture and method for dry powder inhalers
ITMI20010357U1 (en) 2001-06-28 2002-12-30 Plastiape Spa INHALER DEVICE
DE10202940A1 (en) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Cartridge for a powder inhaler
ES2195785B1 (en) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
ES2211344B1 (en) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
BRPI0413129A (en) * 2003-07-29 2006-10-03 Boehringer Ingelheim Int inhalation medicines including betamimetics and anticholinergics
ES2232306B1 (en) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
ES2251866B1 (en) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
ES2251867B1 (en) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
CN1997418B (en) 2004-07-16 2010-08-11 奥米罗有限公司 Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler
ES2298049B1 (en) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. PROCEDURE FOR MANUFACTURING BROMIDE OF 3 (R) - (2-HIDROXI-2,2-DITIEN-2-ILACETOXI) -1- (3-PHENOXIPROPIL) -1-AZONIABICICLO (2.2.2) OCTANO.
EP2100599A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
PL2552424T3 (en) * 2010-04-01 2018-10-31 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation

Also Published As

Publication number Publication date
JP2015517560A (en) 2015-06-22
SG10201609244PA (en) 2016-12-29
AU2013265167A1 (en) 2014-10-30
MX2014014041A (en) 2015-02-12
EA201401309A1 (en) 2015-06-30
CR20140536A (en) 2014-12-15
WO2013175013A1 (en) 2013-11-28
UY34829A (en) 2013-12-31
CL2014003211A1 (en) 2015-06-05
PH12014502619A1 (en) 2015-01-21
DOP2014000269A (en) 2015-02-27
CO7200262A2 (en) 2015-02-27
EP2854808A1 (en) 2015-04-08
AR091161A1 (en) 2015-01-14
CA2871357A1 (en) 2013-11-28
IL235830A0 (en) 2015-01-29
PE20142441A1 (en) 2015-01-17
IN2014DN08421A (en) 2015-05-08
CN104349776A (en) 2015-02-11
US20150118312A1 (en) 2015-04-30
MD20140131A2 (en) 2015-04-30
AU2013265167B2 (en) 2017-08-17
EP2666465A1 (en) 2013-11-27
HK1203050A1 (en) 2015-10-16
US20170128426A1 (en) 2017-05-11
KR20150010757A (en) 2015-01-28

Similar Documents

Publication Publication Date Title
SG11201407110QA (en) Novel dosage form and formulation of abediterol
SG11201407114YA (en) Novel dosage and formulation
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201909325RA (en) 2-amino-quinoline derivatives
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201808682XA (en) Silicone atoms containing ivacaftor analogues
SG11201807708SA (en) Estrogen receptor modulators
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201805645QA (en) Lsd1 inhibitors
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201809799WA (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201809751XA (en) Egfr inhibitor compounds
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201408292YA (en) Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201804050QA (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
SG11201804048WA (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
SG11201402986RA (en) Kinase inhibitors
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201900043TA (en) Antibody formulations
SG11201407599SA (en) Oligonucleotide chelate complex-polypeptide compositions and methods